Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
Glucosamine sulfate
Phoenix Labs
M01AX; M01AX05
Glucosamine sulfate
750 milligram(s)
Film-coated tablet
Product not subject to medical prescription
Other antiinflammatory and antirheumatic agents, non-steroids; glucosamine
Marketed
2011-07-15
DISPATCH NOTE OF PRINT OUT PACKING MATERIAL W A L M A R K Design / Year: DTP operator / Studio: DAVID KNĚŽEK / INTERNAL Proof numb. / Date 1. proof: 7 / 25.06.2018 Used printing material: BO 60 G Special printing technology: NO Used Colours: 1 CUT SIZE (MM): 175 X 265 MM W A L M A R K B L A C K PHARMA CODE: 3765 READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THISMEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. - You must talk to a doctor if you do not feel better or if you feel worse after 1 month. IN THIS LEAFLET: 1. What Arthrimel® is and what it is used for 2. Before you take Arthrimel® 3. How to take Arthrimel® 4. Possible side effects 5. How to store Arthrimel® 6. Further information 1. WHAT ARTHRIMEL® IS AND WHAT IT IS USED FOR Arthrimel® belongs to a group of medicines called other anti-inflammatory and anti-rheumatic agents, non steroids. Arthrimel® is used for the relief of symptoms of mild to moderate osteoarthritis of the knee that has previously been diagnosed by your doctor. Osteoarthritis is a type of joint degeneration that generates symptoms such as stiffness (after sleep or long rest) and pain at motion (e.g. when climbing the stairs or walking along uneven surfaces). 2. BEFORE YOU TAKE ARTHRIMEL® DO NOT TAKE ARTHRIMEL® - If you are allergic (hypersensitive) to: - Glucosamine or to any of the other ingredients of Arthrimel® (see Section 6 “Further Information”) - Shellfish, since Arthrimel® is manufactured from shellfish. TAKE SPECIAL CARE WITH ARTHRIMEL® IF YOU - Suffer from impaired glucose tolerance. More frequent controls of your blood glucose levels may be necessary when starting treatment with Arthr Läs hela dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Arthrimel 750mg Film Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 942mg glucosamine sulfate sodium chloride equivalent to 750 mg glucosamine sulfate. Excipient(s) with known effect: Each tablet contains 75.9 mg (3.3mmol) of sodium. Lactose monohydrate 3.0 mg Lecithin soya (E322) as part of the tablet film-coating. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablets Off-white, oblong shaped film-coated tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Arthrimel tablets are indicated for relief of symptoms in mild to moderate osteoarthritis of the knee as diagnosed by a doctor. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Administration:_ Arthrimel tablets should be swallowed whole. Tablets can be taken with or without food. _Adults and the elderly:_ One Arthrimel tablet should be taken twice daily. Or Two Arthrimel tablets to be taken once daily. Glucosamine is not indicated for the treatment of acute painful symptoms. Relief of symptoms (especially pain relief) may not be experienced until after several weeks of treatment and in some cases even longer. If no relief of symptoms is experienced after 2-3 months, continued treatment with glucosamine should be reevaluated by your healthcare practitioner. Patients should seek medical advice if their symptoms deteriorate after commencing treatment with glucosamine. Additional information on special populations: _Children/ adolescents:_ Safety and efficacy has not been established in children and adolescents, therefore, Arthrimel tablets should not be used in persons under the age of 18 years. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Läs hela dokumentet